Thermo Fisher Scientific Reports Third Quarter 2026 Results
Thermo Fisher reported Q3 2026 revenue of $12.14 billion, up 9% year-over-year with 6% organic growth. GAAP diluted EPS rose 9% to $4.64 while adjusted EPS grew 15% to $6.68; adjusted operating margin expanded to 24.5% from 23.3%. The quarter included new product launches, the Precure venture with Mayo Clinic, completion of the microbiology business divestiture, and strong free cash flow of $2.12 billion.
Key figures
- Eps
- 4.64
- Revenue
- 12137000000
- Guidance
- Updated 2026 financial guidance to be provided during the earnings call (not in release)
- Revenue Yoy
- 9%
- Q3 fcf
- 2115000000
- Ytd fcf
- 4618000000
- Net income
- 1721000000
- Ytd revenue
- 35136000000
- Adjusted eps
- 6.68
- Adjusted eps yoy
- 15%
- Gaap operating income
- 2263000000
- Gaap operating margin
- 18.6%
- Organic revenue growth
- 6%
- Adjusted operating income
- 2968000000
- Adjusted operating margin
- 24.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.